Anderson 16/2/07 15:13 Page 25 Antiviral Chemistry & Chemotherapy 18:25–33 Interaction of 2′-deoxyguanosine triphosphate analogue inhibitors of HIV reverse transcriptase with human mitochondrial DNA polymerase γ Adrian S Ray1†, Joy Y Feng1‡, Eisuke Murakami1§, Chung K Chu2, Raymond F Schinazi3 and Karen S Anderson1* 1Department of Pharmacology, Yale University School of Medicine, New Haven, CT, USA 2Department of Pharmacology and Biomedical Sciences, College of Pharmacy, The University of Georgia, Athens, GA, USA 3Laboratory of Biochemical Pharmacology, Emory University/Veterans Affairs Medical Center, Decatur, GA USA †Current address: Gilead Sciences Inc., Foster City, CA, USA ‡Current address: Gilead Sciences Inc., Durham, NC, USA §Current address: Pharmasset Inc., Princeton, NJ, USA *Corresponding author: Tel: +1 203 785 4526; Fax: +1 203 785 7670; E-mail:
[email protected] Mitochondrial toxicity is a limiting factor in the use transcriptase showed CBV-TP to be approximately of some nucleoside reverse transcriptase inhibitors 800–8,000-fold more selective for its antiviral target of HIV. To further understand the impact of struc- over pol γ relative to the other guanosine analogues. tural features on the incorporation and exonuclease However, DXG-TP and d4G-TP were found to be removal of nucleoside monophosphate (MP) much more selective than previously reported analogues by human mitochondrial DNA poly- values for mitochondrial toxic nucleoside analogues. merase (pol γ), transient kinetic studies were done Structural modelling based on sequence homology with analogues of 2′-deoxyguanosine triphosphate. with other polymerase A family members suggests The kinetic parameters for the incorporation and that an interaction between the ribose oxygen and removal of carbovir (CBV)-MP, dioxolane guanosine arginine 853 in pol γ may play a critical role in (DXG)-MP and 2′,3′-dideoxy-2′,3′-didehydroguano- causing this differential incorporation.